Making generics great again? Allied Patients launches in US

By Flora Southey

- Last updated on GMT

A start-up pharmaceutical firm aiming to make affordable generic medicines has launched in the US.

Hawaii-headquartered Allied Patients, Inc. will rely on a network of more than 20 US-based drug development companies to make its products, and plans to outsource clinical trials.

CEO Eduardo Matto – who is personally financing the venture – says the initiative responds to price increases and drug shortages.

“Allied Patients has a unique vantage point and will develop generic medications for old branded medications that are highly needed. We intend to be the new model for the pharmaceutical industry – do right by patients,” ​he told us.

The firm is currently working on a Phase I programme for a small molecule candidate – Matto did not disclose treatment details – and hopes to eventually move into biologics.

But completing a bioequivalence study within 12 months is the start-up’s initiative objective.

 “Too often in the industry, pilot and pivotal bioequivalence studies have to be repeated because of a poor match,” ​Matto told us.

“Bioequivalence studies account for about 50% of generic development costs, so the study phase is key,” ​he added.

US only

Matto told us the firm will outsource to US firms only: “The goal is fast development that meets our internal controls and FDA [US Food and Drug Administration] standards.”

“One of our key differences is that I do not work with Indian or Chinese firms,” ​said Matto, adding: “They have plenty of good development and clinic sites, but I can think of too many examples of unethical behaviour and underperformance by firms in those countries.”

Related topics Contract Manufacturing & Logistics

Related news